Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology - Wikidata - awgldk - TriplyDB

Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology

Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology

http://www.wikidata.org/entity/Q34943311

about

Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease Age-dependent dysregulation of innate immunity Immunotherapeutic approaches for Alzheimer's disease Microglia demonstrate age-dependent interaction with amyloid-β fibrils APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway.Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta} neurotoxicity in in vitro and in vivo models of Alzheimer's disease.Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus Transcriptomic responses in mouse brain exposed to chronic excess of the neurotransmitter glutamate.Inflammation, microglia, and Alzheimer's disease.Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model MyD88 is dispensable for cerebral amyloidosis and neuroinflammation in APP/PS1 transgenic mice.Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential.Toll-like receptor signaling in neural plasticity and disease.Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice.TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity The effects of MyD88 deficiency on exploratory activity, anxiety, motor coordination, and spatial learning in C57BL/6 and APPswe/PS1dE9 mice.Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.Down syndrome and Alzheimer's disease: Common pathways, common goals.Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer's disease in Han Chinese.Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice.CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.AD vaccines: conclusions and future directions.Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Microglia and inflammation in Alzheimer's disease.Murine models of Alzheimer's disease and their use in developing immunotherapies.Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.Toll-like receptors are key players in neurodegeneration.

P2860

Q21245230-4720AFE6-171F-44DC-8DD4-77856D8C42E7 Q24616286-DC35BF7F-B315-48A3-A172-A1CB598B1672 Q26800956-63CF455B-3685-4BEE-A722-FCEA7996B720 Q26822534-D000D0E0-68E6-4756-80A6-0E92F0779522 Q27022410-2B2A8F32-2571-4EE5-B91C-773A6CF70907 Q28081278-0D0B9842-B841-4454-98BC-497B25EC8B17 Q30427927-B280C21D-9C32-4FB2-95FB-9CC7849B4092 Q30455082-DBB9C3A7-C38A-47CF-BCB9-4A2A8B48457D Q30468802-57A26ED4-DE33-401F-8219-650C15EB3264 Q30491484-0643EC0D-6BE1-402F-9E6C-E6C8C528F147 Q33389941-1F7D1DD4-E766-41E8-A29A-FE1AD984C336 Q33596829-E65DE763-F95E-4990-A2E0-0F03B771D461 Q33664099-5597DB37-1AEA-4B7F-9549-E377DAF8E110 Q33718694-51FE780C-17F9-4E49-8733-089F49E4E430 Q33725397-05C9503C-2206-4E7A-B957-57BF207152BE Q34227162-AAAD0D1E-276E-4F5C-BA78-3D0E5A99B88B Q34375724-059648A1-EC9A-41C0-916F-99EAA1D1E7B0 Q34429979-78FA04CF-618F-44C7-9467-7D54DA0C05B3 Q34510368-8F57C46D-DC00-483E-AD10-384DDCCC1795 Q34984865-BDF7C10A-6BE7-400D-A872-891EF65E7B1A Q35095392-4F6ED6DC-3F48-40FD-949E-47458521B29B Q35203740-C9E697A4-721A-4411-9A5B-9CE8D6830C9C Q35235779-3CB21DFC-23DF-4296-9159-5DE55B9E44C5 Q35624369-2E5D2188-1B6A-4A4A-B260-557F5556E180 Q36421994-F31E0DAB-9101-4D82-86C3-3D4C5C339DA7 Q36583003-5236E3EF-3395-4D34-B070-6D6D57747D00 Q36757252-BEDEE118-F8DC-461C-BACC-A4E9AE7C6032 Q37152691-3845A843-B200-4847-A801-B5F973358EBD Q37220361-CA718CD3-0788-43F4-9558-19A8161FA97E Q37232963-45717844-BF65-4372-9FE1-CD40FB5E50A4 Q37424811-8CEE52C8-7367-46F7-8408-227AC9F8DCB9 Q37438273-171BAF74-FB19-4C52-A26B-D9C9AA1CEA64 Q37555992-BB85E6CF-82DF-437A-9F0F-0B01FC97FEF6 Q37630548-81849FE5-1F6F-42F6-B3DF-EB200DCD2EBE Q37655247-FE8DFC31-F930-4261-AD9E-2AA9B212D6A7 Q37681432-8B15A4A8-E84D-4133-940C-480AAC03A06A Q37703295-13D9DB5B-345D-432E-AF12-45526A5A1092 Q37752915-89B701F1-D3D4-42BD-86BE-0FA1476F9555 Q37832656-BE247964-5821-4B84-AC90-AD9F6C2CA536 Q37880364-74BBE3AB-BDFA-4204-8FEF-A5031AB0106E

P2860

Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology

http://www.wikidata.org/entity/Q34943311

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Induction of toll-like recepto ...... er's disease-related pathology

@ast

Induction of toll-like recepto ...... er's disease-related pathology

@en

Induction of toll-like recepto ...... er's disease-related pathology

@nl

type

label

Induction of toll-like recepto ...... er's disease-related pathology

@ast

Induction of toll-like recepto ...... er's disease-related pathology

@en

Induction of toll-like recepto ...... er's disease-related pathology

@nl

prefLabel

Induction of toll-like recepto ...... er's disease-related pathology

@ast

Induction of toll-like recepto ...... er's disease-related pathology

@en

Induction of toll-like recepto ...... er's disease-related pathology

@nl

P1433

Q34943311-03D6B29C-AC11-4287-AEF0-E21BEE147DE5

P1476

Q34943311-B3204A41-F52C-428C-A4E0-972BE6326628

P2093

Q34943311-5D83D66F-BBFD-45EB-91DC-82C608F62398

Q34943311-5ED10727-AB3E-4F69-9A1E-6849A5F036FF

Q34943311-67F612B3-862C-4C40-9E34-2D7B98EEDF34

Q34943311-A2BF4D4C-A77E-4375-A13C-E7A32546397C

Q34943311-A7AACB18-E9B3-45A9-8DC5-6BBD66C71C6B

Q34943311-C2BC14E5-2655-40CA-AF82-82EEAD90335C

Q34943311-E91F9907-0379-4BC6-8833-99DAEA3B4071

P2860

Q34943311-08602926-7B54-4BC5-AFC6-34F860D3C960

Q34943311-0B068361-F005-44F0-8489-5BEC41E75B58

Q34943311-0F134667-D98E-477F-B1A6-1ACEFC749C75

Q34943311-114F8AA4-B700-453A-9BF9-4D79F362B744

Q34943311-1D178D45-99F6-4050-AE71-C2DCFD332019

Q34943311-1F7802BE-D7A8-467C-86F1-21A5D1EE8D27

Q34943311-27A1CE62-04F9-4234-99CD-C9BD5E59FCFB

Q34943311-2F48A916-18CD-4924-8AA7-993E1BBF2FCF

Q34943311-31799F5A-D00C-4268-A891-27739D05CB6A

Q34943311-31E7DE87-8A0E-44B6-A9A8-FA2E1261EA7D

P304

Q34943311-6FF43ACE-15E5-4D13-8D15-18917AE8227D

P31

Q34943311-9A7DC9CC-FC72-4E40-B36B-D64A9F2ADFED

P356

Q34943311-A6E00661-6CE3-4941-B5E7-4A9EA30277CC

P407

Q34943311-756EA916-C23B-4D24-8CEB-CF782AF046FC

P433

Q34943311-918041AF-B12C-41F6-81C3-3D2D2EDF260B

P478

Q34943311-B239D41E-22F4-4C75-8B92-8AB2AD47B762

P50

Q34943311-6B61EC56-8FA5-4F1F-B4C1-392D59A6C921

Q34943311-ECD9D7C8-3042-4D54-AD03-9686CCA0913D

P577

Q34943311-80BBF126-BEF1-4C4F-930F-0B5A943C97A0

P698

Q34943311-A063EAC4-44BA-4463-A5E2-52D650EC1052

P921

Q34943311-0EFC44D9-373D-4872-B4C0-92DEBEBE6D61

Q34943311-63F32AD6-BE85-4998-B523-7D851C4BF60D

Q34943311-6edf0484-b428-4ee9-8c2a-f82b7e284ed0

P932

Q34943311-1B0DD2D4-A14A-4B95-9797-3234F49DA28B

P356

JNEUROSCI.5715-08.2009

P1433

Journal of Neuroscience

P1476

Induction of toll-like recepto ...... er's disease-related pathology

@en

P2093

Allal Boutajangout

http://www.w3.org/2001/XMLSchema#string

Daniel J Kerr

http://www.w3.org/2001/XMLSchema#string

Daryl S Spinner

http://www.w3.org/2001/XMLSchema#string

Harry C Meeker

http://www.w3.org/2001/XMLSchema#string

Henrieta Scholtzova

http://www.w3.org/2001/XMLSchema#string

Kristyn A Bates

http://www.w3.org/2001/XMLSchema#string

Pankaj D Mehta

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Active and passive immunotherapy for neurodegenerative disorders

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

Bone-marrow-derived microglia: myth or reality?

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification.

Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages

Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils.

P304

1846-1854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.5715-08.2009

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Wisniewski

Richard J. Kascsak

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19211891

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Toll-like receptor

P932

2699573

http://www.w3.org/2001/XMLSchema#string